Entity

Time filter

Source Type

Genève, United Kingdom

Trademark
Preglem Inc. | Date: 2010-07-20

Medicinal preparations for the prevention and treatment of reproductive diseases and disorders; pharmaceutical preparations for the prevention and treatment of reproductive diseases and disorders; veterinary preparations for small and large animals and poultry for the prevention and treatment of reproductive diseases and disorders; and sanitary preparations for medical use; pharmaceutical and biological preparations for diagnostic purposes, treatment and prevention of conditions in human and veterinary medicine, namely, for the prevention and treatment of reproductive diseases and disorders; diagnostic preparations for medical purposes or veterinary purposes. Advertising services; business management; business administration; providing office functions; advertising and promotion services featuring pharmaceutical and biological preparations for diagnostic purposes, treatment and prevention of conditions in human and veterinary medicine; assistance to clients in marketing new products. Scientific and technological services and research and associated design in the field of reproductive medicine; industrial analyses and research in the field of reproductive medicine; research, development, consulting, information, assistance, analyses, medical and scientific research, namely, conducting clinical trials all in the field of formulation and product development of pharmaceutical and biological preparations for diagnostics, treatment and prevention of conditions in human and veterinary medicine. Licensing of intellectual property, namely, acquisition and granting of intellectual property rights on the goods listed in class 5, namely, medicinal preparations for the prevention and treatment of reproductive diseases and disorders, pharmaceutical preparations for the prevention and treatment of reproductive diseases and disorders, veterinary preparations for small and large animals and poultry for the prevention and treatment of reproductive diseases and disorders, and sanitary preparations for medical use, pharmaceutical and biological preparations for diagnostic purposes, treatment and prevention of conditions in human and veterinary medicine, namely, for the prevention and treatment of reproductive diseases and disorders, and diagnostic preparations for medical purposes or veterinary purposes; intellectual property consultation, namely, consulting on services performed for third parties, namely, procedures in relation to compulsory registrations and legal licensing for marketing of pharmaceutical and biological products for diagnostics, treatment and prevention of conditions in human and veterinary medicine on the part of the authorities and public administration, in particular for licensing of medical drugs.


Trademark
Preglem Inc. | Date: 2012-01-17

Pharmaceutical for human use for the prevention and treatment of reproductive diseases and disorders; medical preparations for human use for the prevention and treatment of reproductive diseases and disorders; biotechnological preparations for medical purposes for human use. Advertising and promotion services for pharmaceutical, biotechnological or medical preparations for human use of others; retail and wholesale store services featuring pharmaceutical, biotechnological or medical preparations for human use. Medical services.


Trademark
Preglem Inc. | Date: 2012-07-24

Pharmaceutical and medical preparations for the prevention and treatment of reproductive diseases and disorders, for human use; biotechnological products, namely, medical reagents and solvents for the prevention and treatment of reproductive diseases and disorders, for medical use, for human use; none of these products being for weight-loss or weight-control. Advertising and promotion services for others; retail store services featuring pharmaceutical, biotechnological or medical products for human use, for the prevention and treatment of reproductive diseases and disorders; wholesale store services featuring pharmaceutical, biotechnological or medical products for human use, for the prevention and treatment of reproductive diseases and disorders; none of these services being performed in relation to weight-loss or weight-control. Medical services; none of these services in relation to weight-loss or weight-control.


Trademark
Preglem Inc. | Date: 2009-06-19

Pharmaceutical or medical products for human use; biotechnological products for medical use, for human use. Advertising, promotion and retail sale of pharmaceutical, biotechnological or medical products for human use; grouping, for the benefit of others, pharmaceutical, biotechnological or medical products for human use (excluding their transport) enabling consumers to purchase them conveniently from a wholesaler. Medical services.


Donnez J.,Catholic University of Leuven | Tomaszewski J.,Prywatna Klinika Polozniczo Ginekologiczna | Bouchard P.,University Paris - Sud | Lemieszczuk B.,Gabinet Lekarski Specjalistyczny Sonus | And 8 more authors.
New England Journal of Medicine | Year: 2012

BACKGROUND: The efficacy and side-effect profile of ulipristal acetate as compared with those of leuprolide acetate for the treatment of symptomatic uterine fibroids before surgery are unclear. METHODS: In this double-blind noninferiority trial, we randomly assigned 307 patients with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy with oral ulipristal acetate (at a dose of either 5 mg or 10 mg) or once-monthly intramuscular injections of leuprolide acetate (at a dose of 3.75 mg). The primary outcome was the proportion of patients with controlled bleeding at week 13, with a prespecified noninferiority margin of -20%. RESULTS: Uterine bleeding was controlled in 90% of patients receiving 5 mg of ulipristal acetate, in 98% of those receiving 10 mg of ulipristal acetate, and in 89% of those receiving leuprolide acetate, for differences (as compared with leuprolide acetate) of 1.2 percentage points (95% confidence interval [CI], -9.3 to 11.8) for 5 mg of ulipristal acetate and 8.8 percentage points (95% CI, 0.4 to 18.3) for 10 mg of ulipristal acetate. Median times to amenorrhea were 7 days for patients receiving 5 mg of ulipristal acetate, 5 days for those receiving 10 mg of ulipristal acetate, and 21 days for those receiving leuprolide acetate. Moderate-to-severe hot flashes were reported for 11% of patients receiving 5 mg of ulipristal acetate, for 10% of those receiving 10 mg of ulipristal acetate, and for 40% of those receiving leuprolide acetate (P<0.001 for each dose of ulipristal acetate vs. leuprolide acetate). CONCLUSIONS: Both the 5-mg and 10-mg daily doses of ulipristal acetate were noninferior to oncemonthly leuprolide acetate in controlling uterine bleeding and were significantly less likely to cause hot flashes. (Funded by PregLem; ClinicalTrials.gov number, NCT00740831.) Copyright © 2012 Massachusetts Medical Society. Source

Discover hidden collaborations